Clinical impact of early response to first‐line <scp>VEGFR‐TKI</scp> in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study-Reference-Cited by-同舟云学术

Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study

Published:2022-10-06 Issue:4 Volume:12 Page:4100-4109
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Sobu Ryuta¹,Numakura Kazuyuki¹^ORCID,Naito Sei²,Hatakeyama Shingo³,Kato Renpei⁴^ORCID,Koguchi Tomoyuki⁵,Kojima Takahiro⁶,Kawasaki Yoshihide⁷,Kandori Syuya⁸^ORCID,Kawamura Sadafumi⁹,Arai Yoichi⁹,Ito Akihiro⁷,Nishiyama Hiroyuki⁸,Kojima Yoshiyuki⁵,Obara Wataru⁴,Ohyama Chikara³,Tsuchiya Norihiko²,Habuchi Tomonori¹

Affiliation:

1. Department of Urology Akita University Graduate School of Medicine Akita Japan

2. Department of Urology Yamagata University Faculty of Medicine Yamagata Japan

3. Department of Urology Hirosaki University Graduate School of Medicine Hirosaki Japan

4. Department of Urology Iwate Medical University Morioka Japan

5. Department of Urology Fukushima Prefectural Medical University Fukushima Japan

6. Department of Urology Aichi Cancer Center Nagoya Japan

7. Department of Urology Tohoku University Graduate School of Medicine Sendai Japan

8. Department of Urology and Andrology Tsukuba University Graduate School of Comprehensive Human Sciences Tsukuba Japan

9. Department of Urology Miyagi Cancer Center Natori Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5268

Reference27 articles.

1. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

2. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

3. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

4. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

5. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma